Breast intraductal proliferative lesion
MONDO:0004007A group of non-invasive epithelial proliferations that occur in the ductal system of the breast. The vast majority of cases arise in the terminal ductal lobular units. This category includes atypical ductal hyperplasia, usual ductal hyperplasia, flat epithelial atypia, and ductal carcinoma in situ. There is an increased risk for subsequent development of invasive breast carcinoma.
Also known as: DIN, ductal intraepithelial neoplasia, intraductal proliferative lesion, intraductal proliferative lesion of the breast, mammary intraepithelial neoplasia, ductal type
1594 clinical trials for this condition and its sub-types, 8 tagged with Breast intraductal proliferative lesion itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Breast intraductal proliferative lesion
-
Ductal breast carcinoma in situ 152 trials
1 sub-type
-
Flat ductal epithelial atypia 3 trials
-
Usual ductal breast hyperplasia 0 trials
-
Can a drug shrink precancerous breast cells before surgery?
Disease control CompletedThis study tested whether a drug called ruxolitinib can reduce abnormal breast cells in people with high-risk or precancerous breast conditions like DCIS or atypical hyperplasia. Half of the 84 participants took ruxolitinib for about 15 days before surgery, and the other half too…
Phase 2 • Sponsor: Julie Nangia • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Baby tamoxifen shows promise in preventing breast cancer recurrence
Prevention CompletedThis study follows up on women who took a low dose of tamoxifen (5 mg daily) for three years to see if it continues to prevent breast cancer over the long term. The original trial found a 42% reduction in breast cancer events. Researchers will also combine data from three similar…
Sponsor: Ente Ospedaliero Ospedali Galliera • Aim: Prevention
Last updated Jun 27, 2026 11:00 UTC